We are pleased and honored to have the following impressive group of the country’s top retinal disease thought leaders serve on our scientific advisory board.
Joan W. Miller, M.D.
Chair, Department of Ophthalmology, Harvard Medical School and Chief of Ophthalmology, Massachusetts Eye and Ear and Mass General Hospital
Allen Ho, M.D.
Director, Clinical Retina Research Unit and Retinal Surgeon, Wills Eye Hospital; Professor of Ophthalmology at Thomas Jefferson University School of Medicine
ONL Therapeutics Announces Formation of Scientific Advisory Board
Renowned Retinal Disease Thought Leaders to Help Guide Development of Novel Vision Protection Technology in Age-Related Macular Degeneration (AMD) and Retinal Detachment
ANN ARBOR, MI – October 14, 2015
ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for preserving sight in a range of retinal diseases, today announced the formation
of a scientific advisory board (SAB) comprised
of five of the world’s premier retinal disease thought leaders.
Peter K. Kaiser, M.D.
Chaney Family Endowed Chair in Ophthalmology Research and Professor of Ophthalmology, Cleveland Clinic Lerner College of Medicine
Naresh Mandava, M.D.
Sue Anschutz-Rodgers Chair in Retinal Diseases and Chair, Department of Ophthalmology, University of Colorado
Charles C. Wykoff, M.D., Ph.D.
Director of the Greater Houston Retina Research Foundation with Retina Consultants of Houston